CTOs on the Move

Gilson

www.gison.com

 
Gilson is a Middleton, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.gison.com
  • 3000 Parmenter St
    Middleton, WI USA 53562
  • Phone: 608.836.1551

Executives

Name Title Contact Details

Similar Companies

CHUL Research Center

CHUL Research Center is a Quebec, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cypress Bioscience

Cypress Bioscience, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Myriad

Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.

Crinetics

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company`s lead product candidate, paltusotine (formerly CRN00808), is an investigational, oral, selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 26,000 people in the United States. A Phase 3 program in acromegaly with paltusotine is underway. Crinetics also plans to advance paltusotine into a Phase 2 trial for the treatment of carcinoid syndrome associated with neuroendocrine tumors. The company is also developing CRN04777, an investigational, oral, nonpeptide somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, as well as CRN04894, an investigational, oral, nonpeptide ACTH antagonist for the treatment of Cushing`s disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company`s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company.

BIOMERIX

BIOMERIX is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.